Menarini Industrie Farmaceutiche Riunite: Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data

Related Keywords

Italy ,Boston ,Massachusetts ,United States ,American ,Nassir Habboubi ,Barker Ergun ,Elcin Barker Ergun ,Chhaya Shah ,Exchange Commission ,American Society Of Clinical Oncology ,Menarini Group ,European Union ,Drug Administration ,Radius Health Inc ,Radius Health ,New Drug Application ,Priority Review ,San Antonio Breast Cancer Symposium ,Clinical Oncology ,Chief Executive Officer ,Global Head ,Stemline Therapeutics ,Looking Statements ,Private Securities Litigation Reform Act ,Radiu Annual Report ,Menarini ,Ndustrie ,Armaceutiche ,Yiunite ,Group ,Ladius ,Health ,Ubmit ,Drug ,Application ,Elacestrant ,